Log In
Print
BCIQ
Print
Print this Print this
 

Emend, Ivemend, Proemend, fosaprepitant dimeglumine (MK-0517, ONO-7847)

Also known as: Emend For Injection

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionInjectable formulation of the selective neurokinin 1 (NK1) receptor antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1)
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV); Prevent chemotherapy-induced nausea and vomiting (CINV) in cancer patients ages 6 months-17 years; Treat digestive symptoms resulting from the administration of antineoplastic agents.
Regulatory Designation

Partner

Ono Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today